Shire plc has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and to source additional manufacturers to meet the growing demand for CINRYZE.   Detailed terms of the agreement were not disclosed, but involve milestone payments to Sanquin, including a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to in...